Drug intelligence / Profile preview

APETx2

Development stage
Preclinical
Modality
Peptides, Recombinant Proteins and Enzymes
Administration
In Vitro, Experimental (no Established Clinical Route)
01

Overview

APETx2 is a 42-amino-acid disulfide-rich peptide toxin originally isolated from the sea anemone Anthopleura elegantissima. It is a highly potent and selective inhibitor of acid-sensing ion channel 3 (ASIC3), a proton-gated sodium channel implicated in pain perception and acidosis-related tissue injury. APETx2 blocks homomeric ASIC3 channels (IC50 = 63 nM), with reduced affinity for heteromeric ASIC channels containing ASIC3 subunits, while exhibiting negligible activity against ASIC1a, ASIC1b, ASIC2a, and major voltage-gated sodium or potassium channels. Its analgesic properties have been demonstrated in rodent pain models, and recent research also suggests cardioprotective effects in myocardial ischemia-reperfusion injury models, likely by inhibiting ASIC3 and exerting downstream metabolic and signaling effects. Structurally, APETx2 features three disulfide bridges stabilizing a four-stranded β-sheet fold, sharing a structural family with other sea anemone toxins but exhibiting a unique pharmacological profile. The APETx2 peptide is primarily used as a research tool for deciphering ASIC3 biology and as a template for developing novel analgesic or cardioprotective agents[1][3][4][5][6].

Other names
APETx2APETx-2APETx 2Acid-sensing ion channel 3 (ASIC3) inhibitor peptideSea anemone toxin APETx2
02

Targets

ASIC3ASIC2b/3 (Acid-sensing ion channel 2b/3 heteromer)ASIC1b/3 (Acid-sensing ion channel 1b/3 heteromer)ASIC1a/3 (Acid-sensing ion channel 1a/3 heteromer)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on APETx2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on APETx2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call